Oncoinvent ASA (0RU5) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Welcome to the BergenBio Q4 2024 presentation. I'm Olav Hellebø. I'm the CEO of BergenBio. With me in the room, I have Rune Scheie, our CFO as well, who will join me for the Q&A session at the end. The press release that was sent out last night will probably be the bit that is going to be the most pressing thing to discuss today. But formally, this is the Q4 2024 presentation. So we'll do that bit as well. On the next slide here, you can see a forward-looking statement. So I'm not going to bore you to read that, but I'll flash it here on the screen. So what we're here to talk about today is the discontinuation of our first line SDK11 mutated patients with non-small cell lung cancer. So the study is called our O16 study. And it's a study of Bamsentinib in combination with standard care therapy in first line non-small cell lung cancer. And we were recruiting all the patients with the SCK11 mutation. And Keytruda or Pembrolizumab plus chemo is the standard care. So we added them BAM on top of that. We were encouraged by the efficacy data in the first study, the Phase 1b, in a small population, three patients who had that STK11 mutation. So that was the reason to go into a Phase 2 study in this population. And the review we've done shows lower than expected response rate. And I'll share the data with you in a second. But that's what led to yesterday's announcement about the discontinuation of this study. We do not believe that the data is strong enough for us to be able to go out and raise financing in order to complete the study as we had originally planned it. So this is the study design, and you've seen this before. The phase 1b portion is completed, and now we have started the phase 2 study. The original plan is 40 patients to be enrolled in that study....